10228057

umls-concept:C0003451, umls-concept:C0012655, umls-concept:C0013227, umls-concept:C0019704, umls-concept:C0030946, umls-concept:C0040808, umls-concept:C0205314, umls-concept:C0205466, umls-concept:C0231174, umls-concept:C0441655, umls-concept:C0442967, umls-concept:C0679622, umls-concept:C1274040, umls-concept:C1442488, umls-concept:C1707520

1999-6-21

Twenty human immunodeficiency virus-infected patients experiencing virologic failure of an indinavir- or ritonavir-containing treatment regimen were evaluated in a prospective, open-label study. Subjects received nelfinavir, saquinavir, abacavir, and either another nucleoside analog (n=10) or nevirapine (n=10). Patients treated with the nevirapine-containing regimen experienced significantly greater virologic suppression at week 24 than those not treated with nevirapine (P=.04). Baseline phenotypic drug susceptibility was strongly correlated with outcome in both treatment arms. Subjects with baseline virus phenotypically sensitive to 2 or 3 drugs in the salvage regimen experienced significantly greater virus load suppression than those with baseline virus sensitive to 0 or 1 drug (median week-24 change=-2.24 log and -0.35 log, respectively; P=.01). In conclusion, non-nucleoside reverse transcriptase inhibitors may represent a potent drug in salvage therapy regimens after failure of an indinavir or ritonavir regimen. Phenotypic resistance testing may provide a useful tool for selecting more effective salvage regimens.

eng

AIM

MEDLINE

0022-1899

Print

NLM

1375-81

pubmed-meshheading:10228057-Adult, pubmed-meshheading:10228057-Dideoxynucleosides, pubmed-meshheading:10228057-Drug Resistance, Microbial, pubmed-meshheading:10228057-Drug Therapy, Combination, pubmed-meshheading:10228057-Female, pubmed-meshheading:10228057-HIV Infections, pubmed-meshheading:10228057-HIV Protease Inhibitors, pubmed-meshheading:10228057-HIV-1, pubmed-meshheading:10228057-Humans, pubmed-meshheading:10228057-Indinavir, pubmed-meshheading:10228057-Male, pubmed-meshheading:10228057-Nelfinavir, pubmed-meshheading:10228057-Nevirapine, pubmed-meshheading:10228057-Phenotype, pubmed-meshheading:10228057-Prospective Studies, pubmed-meshheading:10228057-RNA, Viral, pubmed-meshheading:10228057-Reverse Transcriptase Inhibitors, pubmed-meshheading:10228057-Ritonavir, pubmed-meshheading:10228057-Salvage Therapy, pubmed-meshheading:10228057-Saquinavir

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.

Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Controlled Clinical Trial, Research Support, Non-U.S. Gov't